Proteus Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Proteus Syndrome

"Proteus Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Proteus syndrome is a rare condition characterized by overgrowth of the bones, skin, and other tissues. Organs and tissues affected by the disease grow out of proportion to the rest of the body. Proteus syndrome results from a mutation in the AKT1 gene. The AKT1 gene helps regulate cell growth and division (proliferation) and cell death.Literature suggests that mutations in a gene called PTEN have been associated with Proteus syndrome.

According to Thelansis Proteus syndrome is a rare condition with an incidence of less than 1 in 1 million people worldwide.

Competitive landscape of Proteus Syndrome includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Proteus Syndrome across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Proteus Syndrome Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Proteus Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No     Asset     Company           Stage

1            Miransertib       ArQule, Inc.        Phase 2"